Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 167-176

  Pitta, Chara A ^a   Papageorgis, Panagiotis ^a   Charalambous, Christiana ^a   Constantinou, Andreas I ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

4 OHT; 5 AZA; Breast cancer; DNMT; E2; Epigenetics; ER ; ER ; Estrogen receptors; HDAC; MTT; SERMs; Tamoxifen resistance; TSA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ESTROGEN RECEPTOR BETA; HYDROXYTAMOXIFEN; PROTEIN P21; PROTEIN PS2; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE ARREST; CELL STRAIN MCF 7; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; EPIGENETICS; EXPRESSION VECTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

17Β ESTRADIOL; 3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-MONOTETRAZOLIUM BROMIDE; 4-HYDROXYTAMOXIFEN; 4-OHT; 5-2′-DEOXYCYTIDINE; 5-AZA; BREAST CANCER; DNA METHYL TRANSFERASES; DNMT; E(2); EPIGENETICS; ER-Α; ER-Β; ESTROGEN RECEPTOR Α; ESTROGEN RECEPTOR Β; ESTROGEN RECEPTORS; HDAC; HISTONE DEACETYLASE; MTT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SERMS; TAMOXIFEN RESISTANCE; TRICHOSTATIN A; TSA;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; AZACITIDINE; BREAST NEOPLASMS; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MCF-7 CELLS; TAMOXIFEN; TIME FACTORS; TRANSFECTION;

EID: 84880509091     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.031     Document Type: Article

References (44)

1. Fishman J., Osborne M.P., Telang N.T. The role of estrogen in mammary carcinogenesis. Ann. N. Y. Acad. Sci. 1995, 768:91-100.
2. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63:451-486.
3. Klinge C.M., Bambara R.A., Zain S., Hilf R. Estrogen receptor binding to nuclei from normal and neoplastic rat mammary tissues in vitro. Cancer Res. 1987, 47:2852-2859.
4. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392:49-53.
5. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510.
6. Papoutsi Z., Zhao C., Putnik M., Gustafsson J.A., Dahlman-Wright K. Binding of estrogen receptor alpha/beta heterodimers to chromatin in MCF-7 cells. J. Mol. Endocrinol. 2009, 43:65-72.
7. Matthews J., Wihlen B., Tujague M., Wan J., Strom A., Gustafsson J.A. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol. Endocrinol. 2006, 20:534-543.
8. Saji S., Hirose M., Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother. Pharmacol. 2005, 56(Suppl. 1):21-26.
9. Jones P.A. DNA methylation and cancer. Oncogene 2002, 21:5358-5360.
10. Fixemer T., Remberger K., Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003, 54:79-87.
11. Foley E.F., Jazaeri A.A., Shupnik M.A., Jazaeri O., Rice L.W. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000, 60:245-248.
12. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001, 61:2537-2541.
13. Iwao K., Miyoshi Y., Egawa C., Ikeda N., Noguchi S. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int. J. Cancer 2000, 88:733-736.
14. Lau K.M., Mok S.C., Ho S.M. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. USA 1999, 96:5722-5727.
15. Linja M.J., Savinainen K.J., Tammela T.L., Isola J.J., Visakorpi T. Expression of ERalpha and ERbeta in prostate cancer. Prostate 2003, 55:180-186.
16. Sharma D., Saxena N.K., Davidson N.E., Vertino P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006, 66:6370-6378.
17. Skliris G.P., Munot K., Bell S.M., Carder P.J., Lane S., Horgan K., Lansdown M.R., Parkes A.T., Hanby A.M., Markham A.F., Speirs V. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. 2003, 201:213-220.
18. Zhao C., Lam E.W., Sunters A., Enmark E., De Bella M.T., Coombes R.C., Gustafsson J.A., Dahlman-Wright K. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003, 22:7600-7606.
19. Lykkesfeldt A.E., Larsen J.K., Christensen I.J., Briand P. Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. Br. J. Cancer 1984, 49:717-722.
20. Kumar R., Mandal M., Lipton A., Harvey H., Thompson C.B. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res. 1996, 2:1215-1219.
21. Esslimani-Sahla M., Simony-Lafontaine J., Kramar A., Lavaill R., Mollevi C., Warner M., Gustafsson J.A., Rochefort H. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res. 2004, 10:5769-5776.
22. Sweeney E.E., McDaniel R.E., Maximov P.Y., Fan P., Jordan V.C. Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Horm. Mol. Biol. Clin. Investig. 2012, 9:143-163.
23. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., Skaar T.C., Gomez B., O'Brien K., Wang Y., Hilakivi-Clarke L.A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339.
24. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 2004, 11:643-658.
25. Yang X., Ferguson A.T., Nass S.J., Phillips D.L., Butash K.A., Wang S.M., Herman J.G., Davidson N.E. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000, 60:6890-6894.
26. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., Barrow D., Wakeling A.E., Nicholson R.I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
28. Chang C., Norris J.D., Gron H., Paige L.A., Hamilton P.T., Kenan D.J., Fowlkes D., McDonnell D.P. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol. Cell. Biol. 1999, 19:8226-8239.
29. Sharma D., Blum J., Yang X., Beaulieu N., Macleod A.R., Davidson N.E. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol. 2005, 19:1740-1751.
30. Duong V., Licznar A., Margueron R., Boulle N., Busson M., Lacroix M., Katzenellenbogen B.S., Cavailles V., Lazennec G. ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2006, 25:1799-1806.
31. Furst R.W., Kliem H., Meyer H.H., Ulbrich S.E. A differentially methylated single CpG-site is correlated with estrogen receptor alpha transcription. J. Steroid Biochem. Mol. Biol. 2012, 130:96-104.
32. Fan J., Yin W.J., Lu J.S., Wang L., Wu J., Wu F.Y., Di G.H., Shen Z.Z., Shao Z.M. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol. 2008, 134:883-890.
33. Riggins R.B., Schrecengost R.S., Guerrero M.S., Bouton A.H. Pathways to tamoxifen resistance. Cancer Lett. 2007, 256:1-24.
34. Arpino G., Green S.J., Allred D.C., Lew D., Martino S., Osborne C.K., Elledge R.M. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res. 2004, 10:5670-5676.
35. Gutierrez M.C., Detre S., Johnston S., Mohsin S.K., Shou J., Allred D.C., Schiff R., Osborne C.K., Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 2005, 23:2469-2476.
36. Cannings E., Kirkegaard T., Tovey S.M., Dunne B., Cooke T.G., Bartlett J.M. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res. Treat. 2007, 102:173-179.
37. Planas-Silva M.D., Bruggeman R.D., Grenko R.T., Smith J.S. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp. Mol. Pathol. 2007, 82:85-90.
38. Loven M.A., Likhite V.S., Choi I., Nardulli A.M. Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation. J. Biol. Chem. 2001, 276:45282-45288.
39. Ramsey T.L., Risinger K.E., Jernigan S.C., Mattingly K.A., Klinge C.M. Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner. Endocrinology 2004, 145:149-160.
40. Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142:4120-4130.
41. Bardin A., Boulle N., Lazennec G., Vignon F., Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 2004, 11:537-551.
42. Speirs V., Malone C., Walton D.S., Kerin M.J., Atkin S.L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999, 59:5421-5424.
43. Hopp T.A., Weiss H.L., Parra I.S., Cui Y., Osborne C.K., Fuqua S.A. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin. Cancer Res. 2004, 10:7490-7499.
44. Jarvinen T.A., Pelto-Huikko M., Holli K., Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol. 2000, 156:29-35.